Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16706194 | 0.94 | TDP1 (0.55) | TDP1HSD17B10 | |
| SCHEMBL15865701 | 0.94 | TDP1 (0.47) | TDP1HSD17B10 | |
| SCHEMBL12588650 | 0.93 | TDP1 (0.46) | TDP1HSD17B10 | |
| SCHEMBL133943 | 0.86 | TDP1 (0.40) | TDP1 | |
| SCHEMBL12376990 | 0.85 | TDP1 (0.40) | TDP1 | |
| SCHEMBL10198658 | 0.82 | TDP1 (0.37) | TDP1 | |
| SCHEMBL25698473 | 0.82 | TDP1 (0.36) | TDP1 | |
| SCHEMBL13487446 | 0.81 | HSD17B10 (0.48) | TDP1HSD17B10 | |
| SCHEMBL133940 | 0.80 | TDP1 (0.35) | TDP1 | |
| SCHEMBL15180121 | 0.77 | TDP1 (0.70) | TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11678968-B2 | Urological device including a valve retained in a urinary catheter | COLOPLAST A/S (DK) | 2023-06-20 | — | — | US | disclosed |
| US-9993327-B2 | Urological device having a bladder retainer and a valve | COLOPLAST A/S (DK) | 2018-06-12 | — | — | US | disclosed |
| US-9987112-B2 | Method of treating urinary incontinence | COLOPLAST A/S (DK) | 2018-06-05 | — | — | US | disclosed |
| US-20170196675-A1 | UROLOGICAL DEVICE HAVING A BLADDER RETAINER AND A VALVE | COLOPLAST A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| US-9585740-B2 | Urological device | COLOPLAST A/S (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20170020645-A1 | METHOD OF TREATING URINARY INCONTINENCE | COLOPLAST A/S (DK) | 2017-01-26 | — | — | US | disclosed |
| US-9498314-B2 | Urological device | COLOPLAST A/S (DK) | 2016-11-22 | — | — | US | disclosed |
| US-20160317279-A1 | VALVE | COLOPLAST A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| US-20160184075-A1 | BIOMATERIAL | COLOPLAST A/S (DK) | 2016-06-30 | — | — | US | disclosed |
| US-20160113750-A1 | UROLOGICAL DEVICE | VYSERA BIOMEDICAL LIMITED (IE) | 2016-04-28 | — | — | US | disclosed |
| US-20110190905-A1 | GASTROINTESTINAL IMPLANT | VYSERA BIOMEDICAL LIMITED (IE) | 2011-08-04 | — | — | US | disclosed |
| US-20110160836-A1 | VALVE DEVICE | VYSERA BIOMEDICAL LIMITED (IE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160706-A1 | UROLOGICAL DEVICE | VYSERA BIOMEDICAL LIMITED (IE) | 2011-06-30 | — | — | US | disclosed |
| US-20110153027-A1 | Drug Delivery System | VYSERA BIOMEDICAL LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| US-20110152395-A1 | Biomaterial | VYSERA BIOMEDICAL LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| US-7932343-B2 | Biomaterial | VYSERA BIOMEDICAL LIMITED (IE) | 2011-04-26 | — | — | US | disclosed |
| US-20100137998-A1 | ESOPHAGEAL VALVE | VYSERA BIOMEDICAL LIMITED (IE) | 2010-06-03 | — | — | US | disclosed |
| US-20100120934-A1 | BIOMATERIAL | VYSERA BIOMEDICAL LIMITED (IE) | 2010-05-13 | — | — | US | disclosed |
| US-20100121462-A1 | VALVE | VYSERA BIOMEDICAL LIMITED (IE) | 2010-05-13 | — | — | US | disclosed |
| US-20100121461-A1 | VALVE | VYSERA BIOMEDICAL LIMITED (IE) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152395-A1 | Biomaterial | FGB, BMP2, CCL11 | TDP1 588/4885HSD17B10 1249/4885 |
| US-20110153027-A1 | Drug Delivery System | ERBB3, MATR3, ABCB11 | TDP1 1094/4885HSD17B10 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.